Download presentation
Presentation is loading. Please wait.
Published byAndrzej Wasilewski Modified over 5 years ago
1
Fig. 4 High P-eIF2α expression in human prostate tumors with loss of PTEN function is associated with increased risk of metastasis or death after surgery. High P-eIF2α expression in human prostate tumors with loss of PTEN function is associated with increased risk of metastasis or death after surgery. (A) Representative Western blot showing PTEN, MYC, P-PERK, P-eIF2α, and total eIF2α expression with β-actin loading control (Ctrl) in human prostatic RWPE-1 cell lines. (B) Quantification of annexin V–positive cells analyzed by flow cytometry relative to control cells after treatment with DMSO or 500 nM ISRIB for 9 hours (n = 3, mean ± SEM) *P < 0.05, t test. (C) Kaplan-Meier analysis of clinical progression–free survival [progression defined as visceral or bone metastasis or PCSM] for patients with normal PTEN expression versus PTEN loss and relative MYC expression identified by IF from the TMA. (D) Kaplan-Meier analysis of MET/PCSM for patients with normal PTEN expression versus PTEN loss grouped by eIF2α phosphorylation. (E) Cox proportional hazards regression results are shown in a Forest plot of hazard ratios and 95% CI for factors associated with risk of clinical progression after surgery. Independent factors are tumor with PTEN loss/low P-eIF2α or PTEN loss/high P-eIF2α versus a reference group with normal PTEN expression; age in years; PSA in nanograms per milliliter; Gleason score > 7 versus 6; and pathological stage T3-T4 versus T2 at the time of prostatectomy. Hao G. Nguyen et al., Sci Transl Med 2018;10:eaar2036 Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.